SEC Filings
Ligand's $460 Million Of 2030 Convertible Notes Are Now Current Debt Holders Can Convert
Ligand must settle principal in cash if holders convert, and cash and investments fell to $447.4 million after the XOMA purchase.
Ligand Pharmaceuticals (LGND) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
SEC Filings
Ligand must settle principal in cash if holders convert, and cash and investments fell to $447.4 million after the XOMA purchase.
Earnings
Todd Davis found "option value" in the $730 million Zoma portfolio but left earlier earnings targets unchanged.
Earnings
The CFO called the fourth-quarter royalty implied by unchanged guidance "a measured approach" and cited partners that had not yet reported.
Earnings
Royalty revenue rose to $70.3 million in the third quarter, while non-cash investment markdowns pushed Ligand to a $28.5 million net loss.